CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory Immune-related Cytopenia

Inclusion criteria

• Diagnosed with refractory immune-related cytopenia, including immune thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AIHA);
• Age ranging from 18 to 80 years old (inclusive of 18 and 80);
• Expected survival time > 12 months;
• Good function of major organs:

• liver function: ALT/AST < 3 times the upper limit of normal;
• kidney function: creatinine < 100 μmol/L;
• lung function: indoor oxygen saturation ≥ 95%;
• heart function: left ventricular ejection fraction (LVEF) ≥ 50%;
• Peripheral superficial venous blood flow is unobstructed, capable of meeting the requirements for intravenous infusion;
• Karnofsky score ≥ 60, ECOG ≤ 2 points.

Exclusion criteria

• Women who are pregnant (with positive urine/blood pregnancy test results) or breastfeeding;
• Those who have severe underlying heart diseases when participating in this study, including:

• clinically significant atrial fibrillation (AF),
• cardiac conduction block,
• myocardial infarction (within 1 year),
• congestive heart failure (CHF);
• cardiac echocardiography LVEF < 50%;
• New York Heart Association (NYHA) cardiac function classification of III-IV grade;
• Those with active bleeding or bleeding tendencies, and those who need to take anticoagulant drugs;
• Those with organ dysfunction or uncontrollable coexisting diseases;
• History of malignant tumors;
• Those with active chronic hepatitis B or active hepatitis C;
• Known history of human immunodeficiency virus (HIV) infection and/or acquired immunodeficiency syndrome;
• Those with uncontrollable infectious diseases;
• As determined by the investigator, other unsuitable conditions exist.